The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by nab-paclitaxel (Nab-P) as primary chemotherapy continuously combined with dual HER2 blockage for HER2-positive breast cancer: A single-arm phase 2 trial (Brecan Trial).
 
Jixin Yang
No Relationships to Disclose
 
Yuqing Yang
No Relationships to Disclose
 
Xinxin Wen
No Relationships to Disclose
 
Jiang Wu
No Relationships to Disclose
 
Jing Yu
No Relationships to Disclose
 
Lei Wang
No Relationships to Disclose
 
Meiling Huang
No Relationships to Disclose
 
Wenyu Hu
No Relationships to Disclose
 
Wen Ma
No Relationships to Disclose
 
Nanlin Li
No Relationships to Disclose